Treatment of chronic hepatitis C infection is rapidly evolving. Two new drugs, simeprevir and sofosbuvir, have just been approved by the US Food and Drug Administration. Numerous treatment regimens that are more tolerable and more efficacious are in late phase of drug development and are coming to the clinics. In this background, new issues, challenges and opportunities face both the treatment providers as well as patients with chronic hepatitis C infection. It is estimated that 4 million individuals are infected.